$PGY

Pagaya Technologies Ltd. (PGY): Results of Operations and Financial Condition

Pagaya Technologies Ltd. (PGY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Pagaya Reports Second Quarter 2026 Results & Raises Full-Year Net Income Guidance Reported record performance across key metrics • $45 million GAAP net income; up $29 million YoY • $124 million Adjusted EBITDA; up 43% YoY • $387 million Total revenue and other income; up 19% YoY

Original reporting
Published Jul 30, 2026, 11:04 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 30, 2026, 11:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$PGY
Bullish
medium confidence
Mentioned
$PGY
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PGYBullishHigh
01

Why it matters

The filing provides quantified beats versus management outlook and states a full-year net income guidance raise, which can drive immediate repricing of earnings estimates and risk appetite for the name.

02

Market read

Quantified Q2 beats plus an explicit guidance raise are actionable for traders adjusting near-term and full-year earnings expectations.

03

What to watch

Traders may scrutinize the quality of growth (application-to-conversion ~1%) and whether upsized securitizations at higher rates indicate improving unit economics or temporary funding tailwinds.

Relevance 7/10Novelty 9/10Timing: filed pre-market today (2026-07-30) with Q2 results and full-year net income guidance raise

Background

The SEC 8-K includes Item 2.02 and an EX-99.2 shareholder letter summarizing Q2 2026 operating and financial highlights for Pagaya.

Company-level read

Ticker impact

$PGYBullishMedium confidence
Context

Pagaya reports Q2 2026 results with $3.5B network volume, $387M revenue, and raises full-year net income guidance in its shareholder letter.

Expected impact

Bias upward for the next few sessions as traders reprice FY net income expectations; magnitude depends on prior expectations for guidance and margins.

Evidence & confidence

The filing is a primary disclosure (8-K with shareholder letter) and includes multiple quantified beats versus outlook plus a stated guidance increase, which are direct inputs to valuation and positioning.

Market effects

Reinforces demand for consumer credit ABS funding and the viability of product-led underwriting models, potentially supportive for fintech-lending sentiment.

Primarily US consumer credit and ABS market sentiment.

Limited direct global spillover; impacts are mostly within US structured credit and fintech investor appetite.

Counterpoint

Despite strong headline metrics, FRLPC % contracted to 4.2% and the article emphasizes outlook ranges, so investors may focus on sustainability of margins and credit performance.

Key entities

  • Pagaya Technologies Ltd.

    Reports Q2 2026 network volume, revenue, EBITDA, GAAP net income, and raises full-year net income guidance.

  • Gal Krubiner

    Co-founder and CEO quoted in the shareholder letter discussing record profitability and the Auto lending flywheel.

  • Sanjiv Das

    Co-founder and President providing operational update in the shareholder letter.

Related articles

$PGYMed

Pagaya (PGY) Closes Upsized $800 Million AAA Personal Loan ABS Deal

Pagaya Technologies (NASDAQ:PGY) said it closed an upsized $800 million AAA-rated personal loan ABS deal, PAID 2026-4, on June 15, 2026. The transaction involved 39 investors and brings YTD personal loan ABS issuance to nearly $4 billion, its third upsized deal this year. Pagaya reported $40 billion issued since 2018 across 91 ABS deals. Texas Capital initiated coverage June 10 with a Buy rating and $27 target.

$NRSNMed

NeuroSense Therapeutics Ltd. (NRSN): Financial results for H1 2026

NeuroSense Therapeutics Ltd. (NRSN) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 NeuroSense Provides Business Update and Progress for the First Half of 2026 CAMBRIDGE, Mass., September 25, 2026 -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense” or the “Company”), a late-stage clinical biotechnology company focused on developing disease-

$WORMed

WORTHINGTON ENTERPRISES, INC. (WOR): Results of Operations and Financial Condition

WORTHINGTON ENTERPRISES, INC. (WOR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 09 - 23 - 2026 Worthington Enterprises Worthington Enterprises FY2027 Q2 Earnings Call TOTAL PAGES: 15 CORPORATE SPEAKERS: Marcus Rogier Worthington Enterprises; Investor Relations Officer Joseph Hayek Worthington Enterprises; President, Chief Executive Officer Colin